Literature DB >> 21164269

Autoimmune Addison's disease.

Corrado Betterle, Luca Morlin.   

Abstract

Primary adrenocortical insufficiency, or Addison's disease (AD), results from an adrenal cortex hypofunction/dysfunction with a deficient production of glucocorticoids, mineralocorticoids and androgens, and with high levels of both ACTH and plasma renin activity. The prevalence of AD is 110-144 cases per million population in the developed countries. Autoimmune AD is the most frequent etiological form in adult patients, accounting for about 80% of cases, followed by post-tuberculosis AD in 10-15%, the remaining 5% being cases are due to vascular, neoplastic or rare genetic forms. Congenital adrenal hyperplasia is the most frequent form of AD in children and accounts for 72% of cases, whereas autoimmune AD is seen in around 10-15% of cases. The markers of autoimmune AD are adrenal cortex (ACA) or 21-hydroxylase autoantibodies (21-OHAbs) and they are present at diagnosis in more than 90% of cases. In autoimmune AD, the adrenal cortex is infiltrated by lymphocytes and plasma cells and the glands are sclerotic and reduced in volume. Autoimmune AD occurs mainly in middle-aged females, alone or associated with other (clinical, subclinical or potential) autoimmune diseases, giving rise to various forms of autoimmune polyglandular syndrome (type 1, 2 or 4). Replacement therapy with gluco-and mineralocorticoids is life-saving for patients with chronic adrenal insufficiency.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21164269     DOI: 10.1159/000321239

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  24 in total

Review 1.  Postural tachycardia syndrome--current experience and concepts.

Authors:  Christopher J Mathias; David A Low; Valeria Iodice; Andrew P Owens; Mojca Kirbis; Rodney Grahame
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

Review 2.  Addisonian crisis secondary to bilateral adrenal metastases in rectal carcinoma: report of a rare case and literature review.

Authors:  Muhammad Shahid Iqbal; John Hardman
Journal:  J Gastrointest Cancer       Date:  2013-06

Review 3.  Diagnosis and management of pediatric adrenal insufficiency.

Authors:  Ahmet Uçar; Firdevs Baş; Nurçin Saka
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

Review 4.  Adrenal insufficiency in pregnancy: challenging issues in diagnosis and management.

Authors:  Kevin C J Yuen; Lindsay E Chong; Christian A Koch
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

Review 5.  Adrenal cortical insufficiency--a life threatening illness with multiple etiologies.

Authors:  Marcus Quinkler; Felix Beuschlein; Stefanie Hahner; Gesine Meyer; Christof Schöfl; Günter K Stalla
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

6.  Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Authors:  A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

Review 7.  Type 1 diabetes and polyglandular autoimmune syndrome: A review.

Authors:  Martin P Hansen; Nina Matheis; George J Kahaly
Journal:  World J Diabetes       Date:  2015-02-15

Review 8.  Clinical implications of shared genetics and pathogenesis in autoimmune diseases.

Authors:  Alexandra Zhernakova; Sebo Withoff; Cisca Wijmenga
Journal:  Nat Rev Endocrinol       Date:  2013-08-20       Impact factor: 43.330

9.  Case 1-2020: An 11-Year-Old Boy with Vomiting and Weight Loss.

Authors:  Alessio Fasano; Maureen M Leonard; Deborah M Mitchell; George Eng
Journal:  N Engl J Med       Date:  2020-01-09       Impact factor: 91.245

Review 10.  [Addison's disease : Primary adrenal insufficiency].

Authors:  A Pulzer; S Burger-Stritt; S Hahner
Journal:  Internist (Berl)       Date:  2016-05       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.